Browse the evidence

GLP-1 receptor agonists (GLP-1RAs) provide significant cardiorenal protection in patients with type 2 diabetes and obesity, reducing major adverse cardiovascular events (MACE) and slowing kidney disease progression independent of, or in addition to, glycemic control and weight loss.

If you have type 2 diabetes or obesity with heart/kidney risks, GLP-1 medications (like semaglutide or liraglutide) are highly effective. They don't just lower blood sugar; they significantly reduce the risk of heart attacks, strokes, and kidney failure. While they can cause temporary stomach upset, the long-term benefits for your heart and kidneys are substantial and proven by large clinical trials. Discuss these options with your doctor, especially if you have existing heart or kidney conditions.

Obesity is a chronic disease of dysregulated energy balance involving neuroendocrine factors, requiring lifelong, multimodal management (lifestyle, pharmacotherapy, surgery) tailored to individual patient characteristics and evolving goals.

Treat obesity as a chronic disease requiring long-term management. Work with your healthcare provider to create a personalized plan involving lifestyle changes, medications, or surgery based on your specific health needs and goals. Regular follow-up is essential to adjust treatment as your needs change.

High-intensity interval exercise (HIIE) induces time-dependent transcriptomic changes in skeletal muscle that persist for at least 48 hours, with the magnitude of expression for 60% of genes being influenced by cardiorespiratory fitness.

To maximize molecular adaptations, ensure your exercise intensity is relative to your current fitness level (e.g., using lactate threshold or max work rate) rather than a fixed percentage. Recognize that the body's molecular response to exercise continues for up to 48 hours, with significant changes occurring well after the workout ends. This applies to both men and women when fitness levels are comparable.

Semaglutide significantly improves MASH resolution and reduces liver steatosis and enzymes, but does not significantly improve fibrosis regression, with efficacy increasing at doses ≥2.0 mg/week and durations ≥12 months.

If you have MASH, semaglutide is a strong option to resolve active liver inflammation and reduce liver fat, especially if you can tolerate doses of 2.0 mg/week or higher for at least a year. However, do not expect it to reverse existing liver scarring (fibrosis). The primary benefit is halting active injury and reducing metabolic risk factors like weight and blood sugar, which indirectly protects the liver.

Semaglutide and tirzepatide reduce cardiovascular risk and improve cardiac function through pleiotropic mechanisms including endothelial protection, anti-inflammation, and inhibition of cardiomyocyte apoptosis, independent of glycemic control.

If you have obesity and existing heart disease, semaglutide (2.4 mg weekly) significantly lowers your risk of heart attack, stroke, and cardiovascular death, even if you do not have diabetes. This benefit comes from direct protection of your blood vessels and heart muscle, not just weight loss.

GLP-1/GIP receptor agonists (liraglutide, semaglutide, tirzepatide) produce significant weight loss (8-21%) but discontinuation leads to rapid weight regain (approx. two-thirds) and return of cardiovascular risk factors, necessitating long-term maintenance strategies.

GLP-1 medications are highly effective for weight loss but are not a one-time fix. You must plan for long-term use or a structured maintenance program to prevent weight regain. Discuss with your doctor how to manage side effects (like nausea) through diet and titration, and ensure you have a plan for ongoing care, as stopping the medication often leads to regaining two-thirds of the lost weight.

GLP-1 receptor agonists (GLP1RAs) reduce the risk of total stroke by approximately 16-17% and non-fatal stroke by 15-16% in patients with type 2 diabetes, independent of their effects on weight loss.

If you have type 2 diabetes and are at high risk for heart disease or stroke, ask your doctor about GLP-1 receptor agonists. These medications not only help with blood sugar and weight but have been shown in large studies to significantly lower your risk of having a stroke. This benefit exists even if you don't lose a lot of weight.

GLP-1 receptor agonists (e.g., Semaglutide) are effective for weight loss and metabolic stabilization but cause significant weight regain (rebound) upon discontinuation, necessitating long-term management or transition to surgery.

GLP-1 medications like Semaglutide are powerful tools for weight loss and fixing metabolic issues, but they are not a one-time cure. If you stop taking them, you will likely regain most of the weight. Use them to stabilize your health and weight before considering skin removal surgery, or commit to long-term use if surgery is not an option.

Semaglutide (2.4 mg) reduces the risk of major adverse cardiovascular events (MACE) by 20% in patients with cardiovascular disease and obesity, independent of diabetes status.

If you have heart disease and are overweight, Semaglutide may offer a 20% reduction in your risk of heart attack, stroke, or cardiovascular death, in addition to helping with weight loss. This benefit exists even if you do not have diabetes.

GLP-1 receptor agonists provide cardiovascular and renal benefits, including reduced risk of major adverse cardiovascular events (MACE) and improved heart failure symptoms, independent of weight loss.

GLP-1 and GIP/GLP-1 agonists offer significant cardiovascular and renal benefits, reducing the risk of heart attacks, strokes, and heart failure hospitalizations. These benefits occur independently of weight loss, suggesting direct protective effects on organs. They are recommended for patients with obesity and cardiovascular disease or heart failure.

Obesity and central adiposity drive insulin resistance and hypertension through the dysregulation of adipokines (elevated TNF-α, IL-6, leptin; reduced adiponectin), which activate inflammatory pathways like NF-κB and RAAS.

Excess body fat, especially around the abdomen, releases inflammatory hormones (adipokines) that block insulin action and raise blood pressure. This biological process, driven by cytokines like TNF-α and IL-6, makes weight loss and blood sugar control harder. Addressing obesity through lifestyle changes or medications that target these pathways can improve insulin sensitivity and reduce cardiovascular risk.

Resmetirom (80-100 mg daily) improves histological MASH resolution and fibrosis in patients with F2-F3 fibrosis without requiring significant weight loss, while also lowering LDL cholesterol.

If you have moderate to advanced liver scarring (F2-F3) from metabolic issues, Resmetirom is a new daily pill option. It works by targeting liver-specific thyroid receptors to reduce inflammation and scarring, and it also lowers bad cholesterol. You do not need to lose a lot of weight for it to work on the liver, though diet and exercise are still recommended.

GLP-1 receptor agonists (GLP-1RA) significantly reduce major adverse cardiovascular events (MACE), all-cause mortality, and heart failure hospitalizations in patients with type 2 diabetes and obesity, with specific benefits observed in heart failure with preserved ejection fraction (HFpEF).

If you have Type 2 Diabetes and Obesity, especially with heart issues, GLP-1 medications like Semaglutide or Liraglutide are highly effective. They not only help with weight loss but significantly reduce the risk of heart attacks, strokes, and heart failure hospitalizations. While injections can cause temporary stomach issues, the long-term protection for your heart is substantial. Discuss these options with your doctor, particularly if you have heart failure with preserved ejection fraction.

Glucagon-like peptide-1 (GLP-1) receptor agonists, specifically tirzepatide, significantly reduce AHI and improve hypoxic burden in patients with moderate-to-severe OSA and obesity, independent of or adjunct to CPAP use.

If you have moderate to severe sleep apnea and obesity, ask your doctor about Tirzepatide. Recent clinical trials show it significantly reduces breathing interruptions during sleep and improves oxygen levels, even for those already using CPAP. It has received FDA approval for this use. Be prepared for mild stomach issues initially, which usually subside.

Tirzepatide provides cardiovascular protection by reducing major adverse cardiovascular events (MACE) and improving cardiovascular risk scores in patients with type 2 diabetes and obesity.

Tirzepatide not only helps with weight and blood sugar but also lowers your long-term risk of heart attack and stroke. It improves blood pressure and cholesterol, contributing to overall heart health.

GLP-1 receptor agonists (GLP-1RAs) significantly slow chronic kidney disease (CKD) progression and reduce mortality in patients with type 2 diabetes and CKD.

If you have type 2 diabetes and kidney disease, ask your doctor about GLP-1 receptor agonists like semaglutide. These medications not only help with blood sugar and weight but also significantly slow the progression of kidney damage and reduce the risk of heart problems and death. While side effects like nausea and high costs can be barriers, the long-term benefits for kidney and heart health are substantial and supported by major clinical trials.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly improves metabolic parameters associated with biological aging by restoring glycemic control and reducing visceral adiposity.

If you have type 2 diabetes or obesity, Tirzepatide is an FDA-approved option that directly targets the metabolic dysfunction driving biological aging. It works by mimicking hormones that regulate blood sugar and appetite, leading to significant weight loss and improved glycemic control. Discuss with your doctor if this aligns with your health goals.

Targeting obesity with GLP-1-based therapies reduces major adverse cardiovascular events (MACE) in patients with established atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity, even without diabetes.

If you have heart disease and are overweight or obese, even without diabetes, treating your obesity with semaglutide (2.4 mg weekly) can significantly lower your risk of heart attack, stroke, or cardiovascular death by 20%. This treatment addresses the root metabolic driver of your cardiovascular risk.

Semaglutide reduced major adverse cardiovascular events and all-cause mortality.

Semaglutide may be recommended for patients at risk of cardiovascular events.

Tirzepatide showed a favourable safety profile, without increasing the risk of serious adverse events or impacting mortality rates.

Tirzepatide can be used safely in obesity management without significant risk of serious side effects.

Tirzepatide was associated with a significantly lower risk of all-cause mortality compared with bariatric metabolic surgery (BMS) (HR, 0.311; 95% CI, 0.257-0.375; p < 0.0001).

Tirzepatide may be a safer option for reducing mortality in obese patients compared to surgical interventions.

Tirzepatide reduced the risk of major adverse cardiovascular events (MACEs) (HR, 0.743; 95% CI, 0.673-0.821; p < 0.0001).

Tirzepatide may help reduce cardiovascular risks in obese patients.

Tirzepatide reduced the risk of major adverse kidney events (MAKEs) (HR, 0.375; 95% CI, 0.336-0.419; p < 0.0001).

Tirzepatide may be beneficial for kidney health in obese patients.

Semaglutide and tirzepatide resolve metabolic dysfunction-associated steatohepatitis (MASH) in 41% and 53% of patients, respectively, without worsening fibrosis after 52-72 weeks.

These medications can significantly improve liver health in adults with MASH.